Ziv-Aflibercept

Form: Intravenous (IV)

Strength: 25mg/ml

Reference Brands: Zaltrap® (US & EU)

Category: Oncology Cancer Care

Ziv-aflibercept (brand name Zaltrap®) is a recombinant fusion protein used in oncology to treat metastatic colorectal cancer (mCRC) by inhibiting angiogenesis – the process of new blood vessel formation that tumors need to grow. It works by targeting and binding to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with receptors on endothelial cells, thus blocking tumor blood vessel formation. Ziv-aflibercept is typically administered in combination with chemotherapy and is available in the US and EU in an intravenous (IV) formulation